The latest price target for Pulmonx (NASDAQ:LUNG) was reported by D. Boral Capital on November 13, 2025. The analyst firm set a price target for $14.00 expecting LUNG to rise to within 12 months (a possible 457.77% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Pulmonx (NASDAQ:LUNG) was provided by D. Boral Capital, and Pulmonx maintained their buy rating.

The last upgrade for Pulmonx Corp happened on February 27, 2023 when Wells Fargo raised their price target to $15. Wells Fargo previously had an equal-weight for Pulmonx Corp.

The last downgrade for Pulmonx Corp happened on July 31, 2025 when Piper Sandler changed their price target from $9 to $2.5 for Pulmonx Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on November 13, 2025 so you should expect the next rating to be made available sometime around November 13, 2026.

While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a maintained with a price target of $14.00 to $14.00. The current price Pulmonx (LUNG) is trading at is $2.51, which is out of the analyst’s predicted range.